COLL - Collegium Pharmaceutical, Inc.
| Previous Close | 11.78 |
| Open | 11.91 |
| Bid | 12.03 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 11.88 - 12.19 |
| 52 Week Range | 10.01 - 19.83 |
| Volume | 499,147 |
| Avg. Volume | 275,090 |
| Market Cap | 402.65M |
| Beta (3Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.66 |
| Earnings Date | Aug 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.43 |
- Thomson Reuters StreetEvents
Edited Transcript of COLL earnings conference call or presentation 7-Aug-19 8:30pm GMT
Q2 2019 Collegium Pharmaceutical Inc Earnings Call
- GlobeNewswire
Collegium to Participate in Upcoming Investor Conference
STOUGHTON, Mass., Sept. 25, 2019 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain.
- Barrons.com
The Opioid Crisis Has Upended Pain Management. What’s Next for the Industry.
As the litigation seeking to hold corporations responsible for the opioid crisis rolls slowly through the legal system, one thing is changing quickly: the rate at which U.S. doctors prescribe opioids. Investors are looking to what’s next in pain management. In a note in August, Cantor Fitzgerald analyst Brandon Folkes wrote that he expects Xtampza to be “the leading branded extended-release oxycodone over time.” The company said in its second-quarter earnings report that the number of Xtampza ER prescriptions in the second quarter of 2019 rose 51% from the quarter a year earlier.
- GlobeNewswire
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Sept. 03, 2019 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain.
- GlobeNewswire
Collegium Announces Scientific Presentations at PAINWeek 2019 National Conference
Collegium Pharmaceutical, Inc. (COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations relating to rates of abuse and diversion of Xtampza® ER (oxycodone), Nucynta® ER (tapentadol) and Nucynta® (tapentadol) relative to other opioids will be presented at the 13th annual PAINWeek National Conference taking place Sept. 3-7, 2019 in Las Vegas, NV. The posters report analyses of data from several surveillance programs within the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System related to the abuse and diversion of Xtampza® ER compared to other categories of opioids. The poster reports a retrospective study of urine drug testing records of patients admitted to a regional outpatient addiction treatment facility and compares the incidence of urine samples positive for the presence of tapentadol to the incidence of positive tests for other prescription opioids.
Motley FoolAssertio Therapeutics, Inc (ASRT) Q2 2019 Earnings Call Transcript
ASRT earnings call for the period ending June 30, 2019.
Motley FoolCollegium Pharmaceutical, Inc. (COLL) Q2 2019 Earnings Call Transcript
COLL earnings call for the period ending June 30, 2019.
- Zacks
Collegium Pharmaceutical (COLL) Q2 Earnings Surpass Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 152.63% and -1.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Collegium to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update
STOUGHTON, Mass., July 24, 2019 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.
- Simply Wall St.
Imagine Owning Collegium Pharmaceutical (NASDAQ:COLL) And Wondering If The 48% Share Price Slide Is Justified
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Collegium Pharmaceutical Inc (COLL)
How do we determine whether Collegium Pharmaceutical Inc (NASDAQ:COLL) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
- GlobeNewswire
Collegium to Present at Upcoming Investor Conferences
STOUGHTON, Mass., May 29, 2019 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain.
Motley FoolCollegium Pharmaceutical, Inc. (COLL) Q1 2019 Earnings Call Transcript
COLL earnings call for the period ending March 31, 2019.
- Insider Monkey
Were Hedge Funds Right About Dumping Collegium Pharmaceutical Inc (COLL) ?
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of December 31. In this […]
Motley FoolAssertio Therapeutics, Inc (ASRT) Q1 2019 Earnings Call Transcript
ASRT earnings call for the period ending March 31, 2019.
- Zacks
Collegium Pharmaceutical (COLL) Reports Q1 Loss, Tops Revenue Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 83.33% and 6.29%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Collegium Pharmaceutical: 1Q Earnings Snapshot
The Stoughton, Massachusetts-based company said it had a loss of 29 cents per share. Losses, adjusted for stock option expense and non-recurring costs, were 5 cents per share. The results exceeded Wall ...
- GlobeNewswire
Collegium Reports First Quarter 2019 Financial Results
Xtampza® ER Net Product Revenues of $25.1 million in the First Quarter of 2019, a 59% increase over the First Quarter of 2018 and a 36% increase on a Consecutive-Quarter.
- Zacks
Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up?
During Assertio Therapeutics' (ASRT) Q1 conference call, investor focus will be on the company's progress with its neurology franchise and the NDA filing for cosyntropin.
- Motley Fool
2 Big Biotech Stock Upgrades: Can They Reach These Targets?
Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.
- Zacks
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Collegium to Host Conference Call to Discuss First Quarter 2019 Financial Results and Provide Corporate Update
STOUGHTON, Mass., April 24, 2019 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.
- GlobeNewswire
Collegium Appoints Richard Malamut, M.D., as Chief Medical Officer
Collegium Pharmaceutical, Inc. (COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Richard Malamut, M.D., as the company’s first Chief Medical Officer, effective April 1, 2019. In this newly created role, Dr. Malamut will lead Collegium’s Clinical, Medical Affairs, Regulatory and Scientific Affairs functions. “We are excited to have Rick join the Collegium leadership team.
